Valuation: Tvardi Therapeutics, Inc.

Market Cap 31.05M 27.24M 25.23M 23.21M 43.9M 2.97B 44.76M 301M 118M 1.46B 117M 114M 5.04B P/E 2026 *
-1.46x
P/E 2027 * -1.23x
Enterprise Value 31.05M 27.24M 25.23M 23.21M 43.9M 2.97B 44.76M 301M 118M 1.46B 117M 114M 5.04B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
65.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tvardi Therapeutics, Inc.

1 day-5.89%
1 week+64.68%
Current month+74.21%
1 month+25.38%
3 months+8.88%
6 months-27.41%
Current year-23.02%
1 week 2.93
Extreme 2.93
5.69
1 month 1.5
Extreme 1.5
5.69
Current year 1.5
Extreme 1.5
5.69
1 year 1.5
Extreme 1.5
43.65
3 years 1.5
Extreme 1.5
43.65
5 years 1.5
Extreme 1.5
43.65
10 years 1.5
Extreme 1.5
43.65
Date Insider Type Main position Quantity % Market Cap.
06-08Free

Director

6,000 0.0640%
06-08Free

Director

6,000 0.0640%
06-08Free

Director

6,000 0.0640%
Change 5-day change 1-year change 3-year change Capi.($)
-5.89%+64.68%-87.90% - 31.05M
-1.10%+1.53%+3.29%+7.13% 50.61B
+1.07%-2.21%+385.43%+598.65% 39.11B
-0.71%-1.42%+28.19%-7.16% 34.64B
+0.46%-1.62%+20.54%+54.81% 33.79B
-0.06%-0.45%+2.94%+28.70% 26.89B
+0.76%-0.05% - - 16.47B
+0.68%-3.03%+65.35%+117.80% 15.14B
-0.20%+0.58%+15.23%+17.49% 13.85B
+0.71%-1.55%+11.09%-32.55% 12.72B
Average -0.42%-0.72%+49.35%+98.11% 24.33B
Weighted average by Cap. +0.04%-1.12%+80.82%+122.43%

Financials

2026 *2027 *
Net sales - -
Net income -28.48M -24.98M -23.14M -21.29M -40.26M -2.73B -41.05M -276M -108M -1.34B -107M -105M -4.62B -38.74M -33.98M -31.47M -28.96M -54.77M -3.71B -55.83M -375M -147M -1.82B -145M -142M -6.29B
Net Debt - -
Logo Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Employees
12
Date Price Change Volume
26-07-12 US$3.310 +0.91% 2,215,793
26-07-10 US$3.280 -13.68% 2,765,243
26-07-09 US$3.800 -24.00% 7,485,612
26-07-08 US$5.000 +61.29% 39,152,997
26-07-07 US$3.100 +54.23% 70,894,178
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.310USD
Average target price
9.750USD
Spread / Average Target
+194.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TVRD Stock